{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Clear+Cell+Renal+Cell+Carcinoma+Metastatic&page=9", "query": { "condition": "Clear Cell Renal Cell Carcinoma Metastatic", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 545, "total_pages": 55, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Clear+Cell+Renal+Cell+Carcinoma+Metastatic&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Clear+Cell+Renal+Cell+Carcinoma+Metastatic&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T19:13:41.503Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01221506", "title": "Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Carcinoma, Renal Cell" ], "interventions": [ { "name": "Pazopanib", "type": "DRUG" }, { "name": "DCE-MRI and Quantitative Doppler Ultrasound", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2010-10", "completion_date": "2019-04", "has_results": false, "last_update_posted_date": "2020-03-26", "last_synced_at": "2026-10-19T19:13:41.503Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01221506" }, { "nct_id": "NCT05311618", "title": "Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer", "Breast Cancer", "Gastric Cancer", "Non Small Cell Lung Cancer", "Cervical Cancer", "Endocervical Cancer", "Squamous Cell Carcinoma of Head and Neck", "Bladder Urothelial Cancer", "Colorectal Cancer", "Esophageal Cancer", "Ovarian Cancer", "Renal Cell Carcinoma", "Prostate Cancer", "Melanoma", "Mesothelioma", "Cholangiocarcinoma" ], "interventions": [ { "name": "NGM438", "type": "DRUG" }, { "name": "Pembrolizumab (KEYTRUDA ®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NGM Biopharmaceuticals, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 71, "start_date": "2022-05-11", "completion_date": "2025-06", "has_results": false, "last_update_posted_date": "2024-04-01", "last_synced_at": "2026-10-19T19:13:41.503Z", "location_count": 6, "location_summary": "Denver, Colorado • New Haven, Connecticut • Detroit, Michigan + 3 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05311618" }, { "nct_id": "NCT03241173", "title": "A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Malignancies" ], "interventions": [ { "name": "INCAGN01949", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Biosciences International Sàrl", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2017-10-09", "completion_date": "2019-09-17", "has_results": true, "last_update_posted_date": "2022-09-27", "last_synced_at": "2026-10-19T19:13:41.503Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03241173" }, { "nct_id": "NCT00005069", "title": "Arsenic Trioxide in Treating Patients With Metastatic Kidney Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Cancer" ], "interventions": [ { "name": "arsenic trioxide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": null, "start_date": "2000-01", "completion_date": "2001-07", "has_results": false, "last_update_posted_date": "2013-06-19", "last_synced_at": "2026-10-19T19:13:41.503Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005069" }, { "nct_id": "NCT00421512", "title": "A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Renal Cell Carcinoma", "Kidney Cancer" ], "interventions": [ { "name": "Bevacizumab and Sunitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2006-03", "completion_date": "2008-05", "has_results": false, "last_update_posted_date": "2008-11-11", "last_synced_at": "2026-10-19T19:13:41.503Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00421512" }, { "nct_id": "NCT00033956", "title": "Evaluation of M40403 for the Prevention of Dose Limiting Toxicities of High Dose IL-2", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "IL-2 Induced Hypotension" ], "interventions": [ { "name": "M40403", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MetaPhore Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2001-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-19T19:13:41.503Z", "location_count": 3, "location_summary": "Chicago, Illinois • Portland, Oregon • Salt Lake City, Utah", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Portland", "state": "Oregon" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT00033956" }, { "nct_id": "NCT03035630", "title": "Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clear-cell Renal Cell Carcinoma", "RCC", "Kidney Cancer", "Clear-cell Kidney Carcinoma" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" }, { "name": "Sunitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Guru Sonpavde", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2017-05-23", "completion_date": "2020-12", "has_results": false, "last_update_posted_date": "2022-02-15", "last_synced_at": "2026-10-19T19:13:41.503Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT03035630" }, { "nct_id": "NCT01224288", "title": "Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Renal Cell Carcinoma (RCC) Scramble", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "Perfusion CT scan", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2011-01-05", "completion_date": "2029-04-30", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-10-19T19:13:41.503Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01224288" }, { "nct_id": "NCT01896271", "title": "High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Clear Cell Renal Cell Carcinoma" ], "interventions": [ { "name": "IL-2", "type": "DRUG" }, { "name": "Stereotactic Ablative Body Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 30, "start_date": "2013-10-02", "completion_date": "2021-04-20", "has_results": true, "last_update_posted_date": "2021-08-23", "last_synced_at": "2026-10-19T19:13:41.503Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01896271" }, { "nct_id": "NCT01415167", "title": "PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Metastatic Renal Cell Carcinoma", "Metastatic Melanoma" ], "interventions": [], "intervention_types": [], "sponsor": "Prometheus Laboratories", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1690, "start_date": "2011-08", "completion_date": "2018-05", "has_results": false, "last_update_posted_date": "2019-06-13", "last_synced_at": "2026-10-19T19:13:41.503Z", "location_count": 45, "location_summary": "Tucson, Arizona • La Jolla, California • Los Angeles, California + 39 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01415167" } ] }